Navigation Links
Horizon Pharma, Inc. Announces FDA Acceptance of DUEXA(R) New Drug Application for Filing
Date:5/26/2010

.S. alone.

Recently published data also indicates that physicians only co-prescribe GI protective agents 27 percent of the time.  In addition, historical data has shown that, by the third prescription, over 60 percent of patients stop taking their prescribed GI co-therapy.  

About Horizon Pharma

Horizon Pharma, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and chronic inflammation.   Horizon's product portfolio includes innovative therapies in early- and late-stage development that are designed to improve the efficacy, safety and quality of life for patients with chronic pain and inflammation.   Horizon's most advanced product is LODOTRA, a circadian cytokine modulator (CCM) for the treatment of the signs and symptoms of rheumatoid arthritis (RA), which has received a recommendation for granting of a national marketing authorization in certain Member States of the European Union.  L ODOTRA is already launched in Germany.   The company's lead development stage product is DUEXA, a novel, proprietary fixed-dose tablet combining one of the most prescribed NSAIDs in the world, ibuprofen, with a high dose of the most potent H2 antagonist, famotidine, in a single pill.   In two Phase 3 clinical studies (REDUCE-1 and REDUCE-2), DUEXA was shown to significantly reduce the incidence of NSAID-induced upper gastrointestinal (GI) ulcers in patients with mild-to-moderate pain and arthritis.   The Company is financed by leading life-science investors Atlas Venture, Deutsche Bank AG, London, Essex Woodlands Healthcare Ventures, FirstMark Capital, Global Life Science Ventures, NGN Capital, Scale Ventures, Sutter Hill Ventures and TVM Capital.

For more info
'/>"/>

SOURCE Horizon Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Horizon Therapeutics Presents Phase 3 Study Results Identifying Risk Factors for Ulcer Development Among NSAID Users
2. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
3. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
4. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
5. HORIZONS AMI Trial Demonstrates Superior Outcomes with TAXUS(R) Drug-Eluting Stents in Heart Attack Patients
6. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
7. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
8. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
9. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
10. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
11. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... on Omega-3 therapies for cardiovascular disease and overall health is ... accomplishments in 2014 and its outlook for 2015 from the ... Shareholders, We would like to take this opportunity ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015  Profil Institute for ... on diabetes and obesity, announced today a new textbook,  ... Development,  published by Springer, a leading global scientific publisher. ... analyze and illustrate techniques for use in early phase ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/x3hp3g/microbiology ... "Microbiology Testing/Clinical Microbiology Market by Product, Clinical Application ... report to their offering. Clinical ... for the detection of infectious diseases. The respiratory ...
Breaking Medicine Technology:Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... Scientific Corporation (NYSE: BSX ) today announced ... District of Delaware found that Cordis Corporation owed Boston ... which covers intellectual property associated with coronary stent technologies. ... $1 million in reasonable royalties to Boston Scientific. ...
... 2011 Applied Isotope Technologies (AIT), a company ... environmental, healthcare and industrial segments by applying its ... established operations in a 1,500 square foot analytical ... life sciences campus on the south side of ...
Cached Medicine Technology:Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation 2Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation 3Applied Isotope Technologies Opens New Facility in PLSG Life Sciences Campus 2
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store for wedding dresses ... latest collection of wedding dresses , and launches a site-wide ... wedding dress on your big day; the wedding gown is ... wants to find the most suitable wedding dress. Now, we ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... MILWAUKEE, Jan. 5 One in ten people will suffer ... be diagnosed with epilepsy.,Medication will help approximately two-thirds of the ... there are other alternatives. , "Epilepsy ... at Marquette University . "I would have seizures ...
... 5 ev3 Inc. (Nasdaq: EVVV ) today ... scheduled to present at the 27th Annual J.P. Morgan Healthcare ... 2009 at the Westin St. Francis Hotel located at 335 ... the investors, section of the ev3 Web site at ...
... For those looking to go beyond a bachelor,s degree ... (UIC) College of Nursing (CON) offers a variety ... and nurses hoping to apply for the next semester should ... ."Whether you,re interested in a nursing career in public health, ...
... Governor Edward G. Rendell expressed disappointment today that ... their waning days -- would push forward a ... a woman,s access to medical treatments. "I,m very ... midnight regulation that establishes a ,refusal clause, rule ...
... Peake: Entire Health Care System More EffectiveWASHINGTON, Jan. 5 ... and avoid hospitalization by using special technology provided by ... according to a recent study. "The study showed ... it improves patients, access to care and is easy ...
... Care Action Network (SCAN(R)) Health Plan Arizona, a nonprofit Medicare ... to train more than 60 seasoned van drivers about what ... a senior." SCAN has been focused on the unique needs ... to enhancing awareness and skills in the community in dealing ...
Cached Medicine News:Health News:Ending Epileptic Seizures 2Health News:UIC College of Nursing Now Accepting Applications for Graduate Programs 2Health News:UIC College of Nursing Now Accepting Applications for Graduate Programs 3Health News:Gov. Rendell Expresses Disappointment with Bush Administration's Last-Minute Regulation Limiting Patient Care 2Health News:Gov. Rendell Expresses Disappointment with Bush Administration's Last-Minute Regulation Limiting Patient Care 3Health News:VA Data Show Home Health Technology Improves Access to Care 2Health News:SCAN Health Plan Arizona Helps Drivers Understand the Challenges of Aging 2Health News:SCAN Health Plan Arizona Helps Drivers Understand the Challenges of Aging 3
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
Inquire...
... assay for the detection of the APC ... to activated protein C (APC). The test ... the anticoagulant function in vivo and provides ... inherited and acquired APC resistance. Detects the ...
Inquire...
Medicine Products: